IKT Trademark

Trademark Overview

On Thursday, October 25, 2018, a trademark application was filed for IKT with the United States Patent and Trademark Office. The USPTO has given the IKT trademark a serial number of 88169713. The federal status of this trademark filing is REGISTERED as of Tuesday, November 30, 2021. This trademark is owned by Inhibikase Therapeutics, Inc.. The IKT trademark is filed in the Pharmaceutical Products category with the following description:

prescription pharmaceuticals to treat neurodegeneration, infectious disease and cancer
ikt

General Information

Serial Number88169713
Word MarkIKT
Filing DateThursday, October 25, 2018
Status700 - REGISTERED
Status DateTuesday, November 30, 2021
Registration Number6576949
Registration DateTuesday, November 30, 2021
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 26, 2019

Trademark Statements

Description of MarkThe mark consists of a blue molecule containing the white letters "IKT".
Goods and Servicesprescription pharmaceuticals to treat neurodegeneration, infectious disease and cancer
Indication of Colors claimedThe color(s) blue and white is/are claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, November 8, 2018
Primary Code005
First Use Anywhere DateTuesday, August 31, 2021
First Use In Commerce DateTuesday, August 31, 2021

Trademark Owner History

Party NameInhibikase Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressAtlanta, GA 30339
Party NameInhibikase Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAtlanta, GA 30339
Party NameInhibikase Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAtlanta, GA 30339

Trademark Events

Event DateEvent Description
Friday, February 1, 2019ASSIGNED TO EXAMINER
Monday, October 29, 2018NEW APPLICATION ENTERED
Thursday, November 8, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 9, 2018NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, February 1, 2019EXAMINERS AMENDMENT -WRITTEN
Friday, February 1, 2019EXAMINERS AMENDMENT E-MAILED
Friday, February 1, 2019EXAMINER'S AMENDMENT ENTERED
Friday, February 1, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, February 1, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 15, 2019ASSIGNED TO LIE
Wednesday, March 6, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 26, 2019PUBLISHED FOR OPPOSITION
Tuesday, March 26, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 21, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, November 11, 2019SOU TEAS EXTENSION RECEIVED
Monday, November 11, 2019SOU EXTENSION 1 FILED
Monday, November 11, 2019SOU EXTENSION 1 GRANTED
Wednesday, November 13, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 11, 2020SOU TEAS EXTENSION RECEIVED
Monday, May 11, 2020SOU EXTENSION 2 FILED
Monday, May 11, 2020SOU EXTENSION 2 GRANTED
Wednesday, May 13, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 9, 2020SOU TEAS EXTENSION RECEIVED
Monday, November 9, 2020SOU EXTENSION 3 FILED
Monday, November 9, 2020SOU EXTENSION 3 GRANTED
Wednesday, November 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 12, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, May 12, 2021SOU EXTENSION 4 FILED
Wednesday, May 12, 2021SOU EXTENSION 4 GRANTED
Friday, May 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 24, 2021TEAS STATEMENT OF USE RECEIVED
Wednesday, October 27, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, September 24, 2021USE AMENDMENT FILED
Thursday, October 7, 2021STATEMENT OF USE PROCESSING COMPLETE
Thursday, October 7, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, October 26, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, November 30, 2021REGISTERED-PRINCIPAL REGISTER
Wednesday, June 15, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, June 15, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, June 15, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, June 15, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, June 15, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, April 7, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 7, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, April 7, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, April 7, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, April 7, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED

Related Keywords

disease cancer infectious neurodegeneration pharmaceuticals treat prescription